Dean E - Search Results

1

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.

Greystoke A, Steele N, Arkenau HT, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E. Greystoke A, et al. Among authors: dean e. Br J Cancer. 2017 Sep 26;117(7):938-946. doi: 10.1038/bjc.2017.271. Epub 2017 Aug 24. Br J Cancer. 2017. PMID: 28950288 Free PMC article. Clinical Trial.

2

Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic.

Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Dean EJ, et al. Cancer Treat Rev. 2007 Apr;33(2):203-12. doi: 10.1016/j.ctrv.2006.11.002. Epub 2007 Jan 8. Cancer Treat Rev. 2007. PMID: 17210228 Review.

3

X-linked inhibitor of apoptosis protein as a therapeutic target.

Dean EJ, Ranson M, Blackhall F, Dive C. Dean EJ, et al. Expert Opin Ther Targets. 2007 Nov;11(11):1459-71. doi: 10.1517/14728222.11.11.1459. Expert Opin Ther Targets. 2007. PMID: 18028010 Review.

4

Biomarkers of apoptosis.

Ward TH, Cummings J, Dean E, Greystoke A, Hou JM, Backen A, Ranson M, Dive C. Ward TH, et al. Among authors: dean e. Br J Cancer. 2008 Sep 16;99(6):841-6. doi: 10.1038/sj.bjc.6604519. Br J Cancer. 2008. PMID: 19238626 Free PMC article. Review.

5

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.

Dean EJ, Ward T, Pinilla C, Houghten R, Welsh K, Makin G, Ranson M, Dive C. Dean EJ, et al. Br J Cancer. 2010 Jan 5;102(1):97-103. doi: 10.1038/sj.bjc.6605418. Epub 2009 Nov 10. Br J Cancer. 2010. PMID: 19904270 Free PMC article.

6

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.

Ranson M, Shaw H, Wolf J, Hamilton M, McCarthy S, Dean E, Reid A, Judson I. Ranson M, et al. Among authors: dean e. Cancer Chemother Pharmacol. 2010 May;66(1):53-8. doi: 10.1007/s00280-009-1133-3. Epub 2009 Dec 3. Cancer Chemother Pharmacol. 2010. PMID: 19956953 Clinical Trial.

7

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

Ranson M, Reck M, Anthoney A, Hanauske AR, Dean E, Melezinek I, Klingelschmitt G, Kletzl H, Blatter J, Twelves C. Ranson M, et al. Among authors: dean e. Ann Oncol. 2010 Nov;21(11):2233-2239. doi: 10.1093/annonc/mdq246. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20444843 Free article. Clinical Trial.

8

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.

Dean EJ, Cummings J, Roulston A, Berger M, Ranson M, Blackhall F, Dive C. Dean EJ, et al. Neoplasia. 2011 Apr;13(4):339-47. doi: 10.1593/neo.101524. Neoplasia. 2011. PMID: 21472138 Free PMC article.

9

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.

Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, Ranson M. Dean E, et al. Br J Cancer. 2012 Jan 31;106(3):468-74. doi: 10.1038/bjc.2011.555. Epub 2012 Jan 5. Br J Cancer. 2012. PMID: 22223088 Free PMC article. Clinical Trial.

10

Biomarkers of cell death applicable to early clinical trials.

Dean E, Greystoke A, Ranson M, Dive C. Dean E, et al. Exp Cell Res. 2012 Jul 1;318(11):1252-9. doi: 10.1016/j.yexcr.2012.03.020. Epub 2012 Mar 27. Exp Cell Res. 2012. PMID: 22483936 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

931 results

Search Page

Filters